Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced Hepatocellular Carcinoma: A Prospective Study

Next Previous
Trial Profile

Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced Hepatocellular Carcinoma: A Prospective Study

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Sintilimab (Primary)
  • Indications Carcinoma; Liver cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Jun 2022 Results (data cut off: January 20th, 2022) assessing safety and efficacy of Sin-Bev for patients with uHCC who received transarterial chemoembolization (TACE) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 21 Sep 2021 Status changed from recruiting to active, no longer recruiting.
  • 22 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top